Clinical trials: Kidney Donors
Kidney Transplant Candidates
Imlifidase in Living Donor Renal Transplantation Highly Sensitized Recipients
This is a Phase II, pilot, prospective, unicentric trial, to evaluate Imlifidase could improve the transplantability of the highly sensitized patients with good outcomes respect to survival and functionality of the graft.
- Trial name
- LIVEDES (NCT06461546)
- Testing
- Imlifidase
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
EBV Infections, Kidney Transplant
Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney Transplant Recipients Receiving an Organ From EBV Positive Donors
This clinical study will evaluate the safety and tolerability of an IDO-1 inhibitor in patients receiving a kidney transplant. The study includes individuals who have not previously been infected with Epstein-Barr virus (EBV) and…
- Trial name
- IDEP (NCT07368153)
- Testing
- indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor
- Where
- 4 sites in Switzerland
- Volunteers
- 9 people
- Sponsor
- University Hospital, Basel, Switzerland
Kidney Transplantation
CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients
The purpose of this research study is to determine whether kidney transplant recipients who receive belimumab (Benlysta®), combined with the standard of care medications for kidney transplant recipients, is safe and effective in…
- Trial name
- CAMPBEL (NCT03591380)
- Testing
- Belimumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Wisconsin, Madison
End Stage Renal Disease
Panel Reactive Antibody (PRA) Reduction in Sensitized Patients Awaiting Renal Transplantation
The purpose of this study is to offer Panel Reactive Antibodies [PRA] reduction treatment to high responder renal transplant patients who otherwise may never be compatible with a potential organ donor.
- Trial name
- NCT00784979
- Testing
- CMVIG
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Tampa General Hospital
Delayed Graft Function, Kidney Transplantation
Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
The purpose of this study is to evaluate the efficacy of Eculizumab in the prevention of Delayed Graft Function following deceased donor kidney transplantation.
- Conditions
- Delayed Graft Function, Kidney Transplantation, Complement Activity
- Trial name
- NCT01919346
- Testing
- Eculizumab, Normal Saline
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Heeger, Peter, M.D.
Anesthesia, Surgery
Optimized Strict Fluid Management Helps Improve Endpoints After Liver Dissection
During hepatectomy, surgeons often prefer to restrict fluid intake, believing that this can lower central venous pressure (CVP) and reduce intraoperative blood loss.
- Trial name
- SHIELD-pilot (NCT07440121)
- Testing
- restrictive fluid infusion, preload, nitro
- Volunteers
- 90 people
- Sponsor
- Zhihong LU
Renal Transplantation
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
The purpose of this trial is to learn if Belatacept is effective and safe as a first line of immunosuppression treatment in patients undergoing a renal transplant where the donor kidney is obtained in patients with extended…
- Trial name
- BENEFIT-EXT (NCT00114777)
- Testing
- Cyclosporin A, Belatacept Less Intensive Regimen (LI), Belatacept More Intensive Regimen (MI)
- Where
- 79 sites in United States, Argentina and 17 more
- Volunteers
- 595 people
- Sponsor
- Bristol-Myers Squibb
Chronic Kidney Diseases, Genetic Predisposition
APOL1 Genetic Testing Program for Living Donors, Part 2
Living donor (LD) kidney transplantation is the optimal treatment for patients with end-stage kidney disease (ESKD). However, LDs take on a higher risk of future ESKD themselves.
- Trial name
- NCT04999436
- Testing
- APOL1 Counseling Training Program
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Northwestern University
Kidney Transplantation
Normothermic Machine Perfusion (NMP) Versus Hypothermic Machine Perfusion (HMP) in Human Kidney Transplantation
Due to the rising incidence of renal failure and the improvement of organ transplantation technology, the shortage of donor organs has become one of the main problems limiting the development of kidney transplantation.
- Trial name
- NCT05743751
- Testing
- Normothermic machine perfusion, Hypothermic machine perfusion
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhang Tianyu
Immune Tolerance
Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs.
The study will determine whether patients with functioning Human Leukocyte Antigen (HLA) matched kidney transplants for at least one year and who want to discontinue immunosuppressive drugs can be treated with Total Lymphoid…
- Trial name
- NCT03591302
- Testing
- Hematopoietic cell transplantation, Total Lymphoid irradiation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Stephan Busque
Rejection Chronic Renal, Kidney Transplant Rejection
Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection
Our group recently reported that tocilizumab, a humanized monoclonal antibody against the IL-6 receptor, may be effective when administered monthly to patients with chronic antibody-mediated rejection (ABMR).
- Trial name
- NCT03859388
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Cedars-Sinai Medical Center
Renal Failure
Hemopatch Versus No Hemopatch (Renal Transplant)
Kidney transplantation remains one of the most common organ transplanted today but the surgical technique has changed very little from the original pelvic operation.
- Trial name
- NCT02633670
- Testing
- Hemopatch, No Hemopatch
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Kidney Transplantation, Renal Transplantation
Tolerance by Engaging Antigen During Cellular Homeostasis
Anti-rejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent rejection of the new organ.
- Conditions
- Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
- Trial name
- TEACH (NCT03504241)
- Testing
- Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant Rejection
Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants
The Phase 2 primary objective is to evaluate achievement of persistent mixed chimerism and withdrawal of at least one immunosuppression drug for a minimum of 6 months with no episodes of biopsy-proven acute rejection or…
- Trial name
- NCT03605654
- Testing
- MDR-102, Immunosuppressive Agents
- Sponsor
- Medeor Therapeutics, Inc.
Myeloproliferative Disorders, Kidney Cancer
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00787761
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northside Hospital, Inc.
Transplant; Failure, Kidney
Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)
The purpose of this study is to demonstrate that increased dosages of mycophenolic acid in maintenance kidney transplant recipients may cause a reduction in donor-specific antibodies.
- Trial name
- NCT01044303
- Testing
- Myfortic Escalation
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- East Carolina University
Quadratus Lumborum Block, Surgical Wound Infiltration
Surgeon Infiltration QL Block Comparison
The purpose of this study is to learn if using a Quadratus Lumborum (QL) plane injection technique (also called a "nerve block") that numbs the nerves going to the abdominal area improve pain control after surgery compared to…
- Trial name
- NCT03496610
- Testing
- Liposomal Bupivicaine, QL Block
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Duke University